Pharmaceuticals company Alivus Life Sciences announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations for Q4FY25 reached Rs 6,496 million, a growth of 21.1% YoY and 1.2% QoQ. For Q4FY25, EBITDA was at Rs 2,085 million, a growth of 44.2% YoY and 3.8% QoQ. EBITDA margins were at 32.1%, up 520 bps YoY and up 80 bps QoQ. PAT for the quarter stood at Rs 1,419 million and PAT margins were at 21.8%. FY25 Financial Highlights: For FY25, revenue from operations was Rs 23,869 million, a growth of 4.5% YoY. EBITDA for FY25 was at Rs 7,172 million while EBITDA margins stood at 30.0% as compared to 30.1% in FY24 despite the absence of PLI benefit in the current year. For FY25, the company recorded PAT of Rs 4,857 million with PAT margins of 20.3%. During FY25, the company generated a strong free cash flow of Rs 2,328 million leading to Cash and Cash Equivalents (including short term investments) of Rs 5,487 million as of 31 March 2025. Commenting on the company’s performance Yasir Rawjee, MD & CEO, Alivus Life Sciences said, "FY25 was our first full year under the Nirma ownership. Our overall performance has remained consistent with past years, with sustained margins, despite facing external challenges, most notably the loss in PLI revenue. The road ahead has significant opportunities for which we have begun working in earnest via capacity investments and the integration of newer technologies into R&D; and manufacturing operations One of the most encouraging outcomes this year was our ability to maintain EBITDA margins at 30%, even in the absence of PLI benefits and amid market headwinds. This reflects the strength of our diversified portfolio and our continued focus on operational efficiency. Our full-year sales grew by 7.1%, normalizing for the PLI benefit last year and backed by healthy contributions from both GPL and Non-GPL segments. As we move into FY26, we remain committed to delivering sustainable growth with stable margins, while continuing to invest in our core growth drivers, expanding our product pipeline, and scaling our operations to create long-term value." Tushar Mistry, CFO, Alivus Life Sciences said, "We delivered strong revenue growth of 21.1% in Q4FY25, with 520 bps improvement in EBITDA margins at 32.1%. We concluded the year on a positive note, with full-year revenue growth of 7.1% normalised for PLI benefits, which has been in line with our earlier guidance. For FY25, both gross margins and EBITDA margins remained stable at ~55% and ~30% respectively, supported by a favourable product mix and cost discipline. Notably, we maintained EBITDA margins of 30% without PLI scheme benefits, a strong validation of our operational resilience. Alivus Life Sciences has generated healthy cash flows of Rs 233 Crore during the year, which supports our growth initiatives while enabling us to maintain a debt-free balance sheet." Result PDF